New disc-based technologies for diagnostic and research applications

Psychiatric Genetics

Volumn 12, Issue 4, 2002, Pages 193-206

  Barathur, Raj ^a   Bookout, Jack ^a   Sreevatsan, Srinand ^a   Gordon, John ^a   Werner, Martina ^a   Thor, Gautam ^a   Worthington, Mark ^a  

^a Burstein Laboratories   (United States)

Author keywords

CD DVD discs; Gene variants; Genotyping; MEMS; Microarrays; Nanotechnology; Neurogenomics; Neurologic disorders; Optical discs; Pathogen detection; Pharmacogenomics

Indexed keywords

BIOMEMS MICROELECTROMECHANICAL SYSTEMS; COMPACT DISK; DIAGNOSTIC PROCEDURE; DNA MICROARRAY; DRUG ACTIVITY; ENVIRONMENTAL FACTOR; FUTUROLOGY; GENE TECHNOLOGY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOASSAY; INFECTION; NANOTECHNOLOGY; PRIORITY JOURNAL; REVIEW; TECHNOLOGY;

GENETIC TECHNIQUES; GENOTYPE; HUMANS; IMMUNOLOGIC TECHNIQUES; MOLECULAR BIOLOGY; NERVOUS SYSTEM DISEASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; VARIATION (GENETICS);

EID: 0036910945     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041444-200212000-00002     Document Type: Review

References (97)

1. Acha PN, Szyfres B (1987). Zoonoses and Communicable Diseases Common to Man and Animals, Scientific publication series No. 503, 2nd ed. Washington, DC: Pan American Health Organization. pp. 24-45.
2. Altshuler D, Pollara VJ, Cowles CR, Van Etten WJ, Baldwin J, Linton L, Lander ES (2000). An SNP map of the human genome generated by reduced representation shotgun sequencing. Nature 407:513-516.
3. Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, et al. (1997). Genotype, viral load and age as independent predictors of treatment outcome of interferon-α 2a treatment in patients with chronic hepatitis C. Scand J Infect Dis 29:17-22.
4. Bjursell C, Wahlstrom J, Berg K, Stibler H, Kristiansson B, Matthijs G, Martinsson T (1998). Detailed mapping of the phosphomannomutase 2 (PMM2) gene and mutation detection enable improved analysis for Scandinavian CDG type I families. Eur J Hum Genet 6:603-611.
5. Bjursell C, Erlandson A, Nordling M, Nilsson S, Wahlstrom J, Stibler H, Kristiansson B, Martinsson T (2000). PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families. Hum Mutat 16:395-400.
6. Bowtell DDL (1999). Options available-from start to finish-for obtaining expression data by microarray. Nat Genet Suppl 21:25-31.
7. Chasse JF, Paul V, Escanez R, Kamoun P, London J (1997). Human cystathionine beta-synthase: Gene organization and expression of different 5-prime alternative splicing. Mammalian Genome 8:917-921.
8. Chuang DT, Fisher CW, Lau KS, Griffin TA, Wynn RM, Cox RP (1991). Maple syrup urine disease: Domain structure, mutations and exon skipping in the dihydrolipoyl transacylase (E2) component of the branched-chain alpha-keto acid dehydrogenase complex. Molec Biol Med 8:49-63.
9. Chuang DT, Shih VE (1995). Disorders of branched chain amino acid and keto acid metabolism. In: Metabolic and Molecular Bases of Inherited Disease, 7th Ed., Scriver CR, Beaudet AL, Sly WS, Valle D (editors). New York: McGraw-Hill. pp. 1239-1277.
10. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
11. Daiger SP, Reel L, Huong SS, Zeng YT, Low H, Okano Y, et al. (1989). Polymorphic DNA haplotypes at the phenylalanine hydroxylase (PAH) locus in Asian families with phenylketonuria (PKU). Am J Hum Genet 45:319-324.
12. Dancis J, Hutzler J, Rokkones T (1967). Intermittent branched-chain ketonuria. Variant of maple-syrup-urine disease. N Engl J Med 276:84-89.
13. Davidson BL, Pashmforoush M, Kelley WN, Palella TD (1989). Human hypoxanthine-guanine phosphoribosyltransferase deficiency: The molecular defect in a patient with gout (HPRT-Ashville). J Biol Chem 264:520-525.
14. Degioanni A, Darlu P (1994). Analysis of the molecular variance at the phenylalanine hydroxylase (PAH) locus. Eur J Hum Genet 2:166-176.
15. De Jonghe C, Cruts M, Rogaeva EA, Tysoe C, Singleton A, Vanderstichele H, et al. (1999). Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased Abeta42 secretion. Hum Molec Genet 8:1539-1540.
16. DiLella AG, Kwok SCM, Ledley FD, Marvit J, Woo SLC (1986). Molecular structure and polymorphic map of the human phenylalanine hydroxylase gene. Biochemistry 25:743-749.
17. Dorsch M, Moreno E, Stackebrandt E (1989). Nucleotide sequence of the 16S rRNA from Brucella abortus. Nucleic Acids Res 17:1765-1765.
18. Edwards A, Civitello A, Hammond HA, Caskey CT (1991). DNA typing and genetic mapping with trimeric and tetrameric tandem repeats. Am J Hum Genet 49:746-756.
19. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R (1992). Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12:241-253.
20. Elpeleg ON, Shaag A, Glustein JZ, Anikster Y, Joseph A, Saada A (1997). Lipoamide dehydrogenase deficiency in Ashkenazi Jews: An insertion mutation in the mitochondrial leader sequence. Hum Mutat 10:256-257.
21. Elsas LJ II, Lai K (1998). The molecular biology of galactosemia. Genet Med 1:40-48.
22. Emilein G, Maloteaux JM, Geurts M, Owen J (1999). Dopamine receptors and schizophrenia: Contribution of molecular genetics and clinical neuropsychology. J Neuropsychol 2:197-227.
23. Evans WE, Relling MV (1999). Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487-491.
24. Farlow MR, Lahiri DK, Poirer J (1996). Apolipoprotein E genotype and gender influence response to tarcrine therapy. Ann NY Acad Sci 802:101-110.
25. Farlow MR, Lahiri DK, Poirer J, Davignan J, Hui S (1998). Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 50:669-677.
26. Fekete G, Plattner R, Crabb DW, Zhang B, Harris RA, Heerema N, Palmer CG (1989). Localization of the human gene for the E1-alpha subunit of branched chain keto acid dehydrogenase (BCKDHA) to chromosome 19q13.1-q13.2. Cytogenet Cell Genet 50:236-237.
27. Finckh U, Muller-Thomsen T, Mann U, Eggers C, Marksteiner J, Meins W, et al. (2000). High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am J Hum Genet 66:110-117.
28. Fisher CR, Chuang JL, Cox RP, Fisher CW, Star RA, Chuang DT (1991a). Maple syrup urine disease in Mennonites: Evidence that the Y393N mutation in E1-alpha impedes assembly of the E1 component of branched-chain alpha-keto acid dehydrogenase complex. J Clin Invest 88:1034-1037.
29. Fisher CW, Lau KS, Fisher CR, Wynn RM, Cox RP, Chuang DT (1991b). A 17-bp insertion and a phe215-tocys missense mutation in the dihydrolipoyl transacylase (E2) mRNA from a thiamine-responsive maple syrup urine disease patient WG-34. Biochem Biophys Res Commun 174:804-809.
30. Fodor SP, Rava RP, Huang XC, Pease AC, Holmes CP, Adams CL (1993). Multiplexed biochemical assays with biological chips. Nature 364:555-556.
31. Fox KF, Fox A, Nagpal M, Steinberg P, Heroux K (1998). Identification of Brucella by ribosomal-spacer-region PCR and differentiation of Brucella canis from other Brucella ssp. pathogenic for humans by carbohydrate profiles. J Clin Microbiol 36:3217-3222.
32. Fujimori S, Hidaka Y, Davidson BL, Palella TD, Kelley WN (1988). Identification of a single nucleotide change in a mutant gene for hypoxanthine-guanine phosphoribosyltransferase (HPRT-Ann Arbor). Hum Genet 79:39-43.
33. Gibbs RA, Caskey CT (1987). Identification and localization of mutations at the Lesch-Nyhan locus by ribonuclease A cleavage. Science 236:303-305.
34. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-706.
35. Griffiths PV, Demellweek C, Fay N, Robinson PH, Davidson DC (2000). Wechsler subscale IQ and subtest profile in early treated phenylketonuria. Arch Dis Child 82:209-215.
36. Guttler F, Woo SLC (1986). Molecular genetics of PKU. J Inherit Metab Dis 9(suppl 1):58-68.
37. Hagberg BA, Blennow G, Kristiansson B, Stibler H (1993). Carbohydrate-deficient glycoprotein syndromes: Peculiar group of new disorders. Pediatr Neurol 9:255-262.
38. Hahn SH, Krasnewich D, Brantly M, Kvittingen EA, Gahl WA (1995). Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1. Hum Mutat 6:66-73.
39. Herring WJ, Litwer S, Weber JL, Danner DJ (1991). Molecular genetic basis of maple syrup urine disease in a family with two defective alleles for branched chain acyltransferase and localization of the gene to human chromosome 1. Am J Hum Genet 48:342-350.
40. Hofman KJ, Antonarakis SE, Missiou-Tsangaraki S, Boehm CD, Valle D (1989). Phenylketonuria in the Greek population. Haplotype analysis of the phenylalanine hydroxylase gene and identification of a PKU mutation. Mol Biol Med 6:245-250.
41. Hofman KJ, Steel G, Kazazian HH, Valle D (1991). Phenylketonuria in US blacks: Molecular analysis of the phenylalanine hydroxylase gene. Am J Hum Genet 48:791-798.
42. Hong YS, Kerr DS, Craigen WJ, Tan J, Pan Y, Lusk M, Patel MS (1996). Identification of two mutations in a compound heterozygous child with dihydrolipoamide dehydrogenase deficiency. Hum Molec Genet 5:1925-1930.
43. Hsia D Y-Y (1967). Clinical variants of galactosemia. Metabolism 16:419-437.
44. Hutton M, Busfield F, Wragg M, Crook R, Perez-Tur J, Clark RF, et al. (1996). Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease. Neuroreport 7:801-805.
45. Ingelman-Sundberd M (1998). Functional consequences of polymorphism of xenobiotic metabolizing enzymes. Toxicol Lett 102-103:155-160.
46. Jaeken J, De Cock P, Stibler H, Van Geet C, Kint J, Ramaekers V, Carchon H (1993). Carbohydrate-deficient glycoprotein syndrome type II. J Inherit Metab Dis 16:1041.
47. Joos TO, Schrenk M, Hopfl P, Kroger K, Chowdhury U, Stoll D et al. (2000). A microarray enzyme-linked immunosorbant assay for autoimmune diagnostics. Electrophoresis 21:2641-2650.
48. Kaufman S (1999). A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients. Proc Natl Acad Sci USA 96:3160-3164.
49. Kennedy GC (2000). The impact of genomics on therapeutic drug development. EXS 89:1-10.
50. Kiddo H, Maquieira A, Hammock BD (2000). Disc-based immunoassay microarrays. Anal Chim Acta 411:1-11.
51. Kim S, Dougherty ER, Bittner ML, Chen Y, Sivakumar K, Metzer P (2000). General nonlinear framework for the analysis of gene interaction via multivariate expression arrays. J Biomed Optics 5:411-424.
52. Kjaergaard S, Skovby F, Schwartz M (1998). Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. Eur J Hum Genet 6:331-336.
53. Kjaergaard S, Skovby F, Schwartz M (1999). Carbohydrate-deficient glycoprotein syndrome type 1A: Expression and characterisation of wild type and mutant PMM2 in E. coli. Eur J Hum Genet 7:884-888.
54. Kleyn PW, Vesell ES (1998). Genetic variation as a guide to drug development. Science 281:1820-1821.
55. Kondo I, Mizugishi K, Yoneda Y, Hashimoto T, Kuwajima K, Yuasa L, et al. (1999). Missense mutations in phosphomannomutase 2 gene in two Japanese families with carbohydrate-deficient glycoprotein syndrome type 1. Clin Genet 55:50-54.
56. Konecki DS, Lichter-Konecki U (1991). The phenylketonuria locus: Current knowledge about alleles and mutations of the phenylalanine hydroxylase gene in various populations. Hum Genet 87:377-388.
57. Kost GJ (2000). Connectivity: The millennium challenge for point-of-care testing. Arch Pathol Lab Med 124:1108-1110.
58. Krajden M (1995). Molecular detection of hepatitis C virus: Impact of detection methodology on clinical and laboratory correlations. Crit Rev Clin Lab Sci 32:41-66.
59. Kraus JP, Janosik M, Kozich V, Mandell R, Shih V, Sperandeo MP, et al. (1999). Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat 13:362-375.
60. Kupferschmid TD, Calicchio T, Budowle B (1999). Maine Caucasian population DNA database using twelve short tandem repeat loci. J Forensic Sci 44:392-395.
61. Langley SD, Lai K, Kembrue PP, Hjelm LN, Elsas LJ (1997). Molecular basis of Duarte and Los Angeles variant galactosemia. Am J Hum Genet 60:366-372.
62. Liu T-C, Kim H, Arizmendi C, Kitano A, Patel MS (1993). Identification of two missense mutations in a dihydrolipoamide dehydrogenase-deficient patient. Proc Natl Acad Sci USA 90:5186-5190.
63. Louis M, Tanguay RM (1997). Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: Overview. Hum Mutat 9:291-299.
64. Matthijs G, Schollen E, Pardon E, Veiga-Da-Cunha M, Jaeken J, Cassiman J-J, Van Schaftingen E (1997). Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nat Genet 16:88-92.
65. Matthijs G, Schollen E, Heykants L, Grunewald S (1999). Phosphomannomutase deficiency: The molecular basis of the classical Jaeken syndrome (CDGS type Ia). Molec Genet Metab 68:220-226.
66. Matthijs G, Schollen E, Bjursell C, Erlandson A, Freeze H, Imtiaz F, et al. (2000). Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat 16:386-394.
67. Miller MS, McCarver DG, Bell DA, Eaton DL, Goldstein JA (1997). Genetic polymorphisms in human drug metabolic enzymes. Fundam Appl Toxicol 40:1-14.
68. Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogler H, et al. (1990). Neurologic crises in hereditary tyrosinemia. N Engl J Med 322:432-437.
69. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. (1985). The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37:1-31.
70. Natt E, Kao F-T, Rettenmeier R, Scherer G (1986). Assignment of the human tyrosine aminotransferase gene to chromosome 16. Hum Genet 72:225-228.
71. Natt E, Kida K, Odievre M, Di Rocco M, Scherer G (1992). Point mutations in the tyrosine aminotransferase gene in tyrosinemia type II. Proc Natl Acad Sci 89:9297-9301.
72. Nicoltti P (1980). The epidemiology of brucellosis. Adv Vet Sci Comp Med 24:69-98.
73. Nilsberth C, Westlind-Danielsson A, Eckman CB, Forsell C, Axelman K, Luthman J, et al. (2000). The Arctic APP mutation (E693G) causes Alzheimer's disease through a novel mechanism: Increased amyloid β protofibril formation and decreased amyloid β levels in plasma and conditioned media. Neurobiol Aging 21(suppl 1):S58.
74. Nobukuni Y, Mitsubuchi H, Akaboshi I, Indo Y, Endo F, Yoshioka A, Matsuda I (1991). Maple syrup urine disease: Complete defect of the E1-beta subunit of the branched chain alpha-ketoacid dehydrogenase complex due to a deletion of an 11-bp repeat sequence which encodes a mitochondrial targeting leader peptide in a family with the disease. J Clin Invest 87:1862-1866.
75. Paine RS (1957). The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria). Pediatrics 20:290-302.
76. Patel MS, Harris RA (1995). Mammalian alpha-keto acid dehydrogenase complexes: Gene regulation and genetic defects. FASEB J 9:1164-1172.
77. Reichardt JKV, Woo SLC (1990). Missense mutations in galactosemia (abstract). Am J Hum Genet 47(suppl):A164.
78. Reichardt JKV, Woo SLC (1991). Molecular basis of galactosemia: Mutations and polymorphisms in the gene encoding human galactose-1-phosphate uridyltransferase. Proc Natl Acad Sci USA 88:2633-2637.
79. Renwick PJ, Birley AJ, McKeown CME, Hulten M (1995). Southern analysis reveals a large deletion at the hypoxanthine phosphoribosyltransferase locus in a patient with Lesch-Nyhan syndrome. Clin Genet 48:80-84.
80. Roest Crollius H, Jaillon O, Bernot A, Dasilva C, Bouneau L, Fischer C, et al. (2000). Estimate of human gene number provided by genome-wide analysis using Tetraodon nigroviridis DNA sequence. Nat Genet 25:235-238.
81. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. (2001). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-933.
82. Scherer SW, Otulakowski G, Robinson BH, Tsui L-C (1991). Localization of the human dihydrolipoamide dehydrogenase gene (DLD) to 7q31-q32. Cytogenet Cell Genet 56:176-177.
83. Schweitzer S, Shin Y, Jakobs C, Brodehl J (1993). Long-term outcome in 134 patients with galactosaemia. Eur J Pediatr 152:36-43.
84. Scriver CR, Kaufman S, Woo SLC (1989). The hyperphenylalaninemias. In: The Metabolic Basis of Inherited Disease, 6th Ed., Scriver CR, Beaudet AL, Sly WS, Valle D (editors). New York: McGraw-Hill. pp. 495-546.
85. Shi MM, Mehrens D, Dacus K (2001). Pharmacogenomics: Changing the health care paradigm. Modern Drug Discovery 4:27-32.
86. Sreevatsan S, Bookout JB, Ringpis F, Perumaala S, Ficht TA, Adams LG, et al. (2000). A multiplex approach to molecular detection of Brucella abortus and/or Mycobacterium boris infection in cattle. J Clin Microsc 38:2602-2610.
87. Timmers C, Grompe M (1996). Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I. Hum Mutat 7:367-369.
88. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ (1996). High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet 59:1262-1267.
89. Van Schaftingen E, Jaeken J (1995). Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. FEBS Lett 377:318-320.
90. Venter JC, Adams MD, Meyers EW, Li PW, Mural RJ, Sutton GG, et al. (2001). The sequence of the human genome. Science 291:1304-1351.
91. Visy JM, Le Coz P, Chadefaux B, Fressinaud C, Woimant F, Marquet J, et al. (1991). Homocystinuria due to 5,10-methylenetetra-hydrofolate reductase deficiency revealed by stroke in adult siblings. Neurology 41:1313-1315.
92. Warne D, Watkins C, Bodfish P, Nyberg K, Spurr NK (1991). Tetranucleotide repeat polymorphism at the human beta-actin related pseudogene 2 (ACTBP2) detected using the polymerase chain reaction. Nucl Acids Res 19:6980.
93. Weber WW (1997). Pharmacogenomics. New York: Oxford University Press.
94. Wilson JM, Frossard P, Nussbaum RL, Caskey CT, Kelley WN (1983). Human hypoxanthine-guanine phosphoribosyltransferase: Detection of a mutant allele by restriction endonuclease analysis. J Clin Invest 72:767-772.
95. Wong PWK, Justice P, Smith GF, Hsia DY-Y (1972). A case of classical maple syrup urine disease, 'thiamine non-responsive'. Clin Genet 3:27-33.
96. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominga T, Persing DH, Group CS (1996). Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy. Ann Int Med 125:634-639.
97. Zneimer SM, Lau KS, Eddy RL, Shows TB, Chuang JL, Chuang DT, Cox RP (1991). Regional assignment of two genes of the human branched-chain alpha-keto acid dehydrogenase complex: The E1-beta gene (BCKDHB) to chromosome 6p21-22 and the E2 gene (DBT) to chromosome 1p31. Genomics 10:740-747.